Avid Bioservices Inc (CDMO)

[realist1]

RE "survival data, neat phrase huh, from the Sunrise trial."

Realistically, that's a year or more away.
And your "billions" is tied to "multiple cancers.
And we're not talking multiple cancers YET, we're talking ONLY 2nd line therapy for NSCLC, which the analysts have said is $500 million market and
1. No one ever gets 100% of a market and
2. There years of sales ramp.

If (and that's still an "IF") sunrise has good data - that's 2016.
FDA approve maybe 2017.
Sales ramp 2018-2020.
Maybe $350 million in sales, maybe 5 X sales = $1.75 billion / ~500 million shares (remember were talking ~5 years of possible dilution) = $3.50 stock.
And that's if everything goes really well and we all know it won't.

Getting back to OTHER INDICATIONS:
MORE many years away and not worthy of discussion yet.
Seriously, they're just talking about stating phase 2's for other indications.

Bottom line, when people toss around multiple billions numbers, it's all fantasy.